Lyell Immunopharma, Inc. (LYEL) › Operating IncomeLyell Immunopharma, Inc. (LYEL) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2019: -$102.09M2020: -$211.94M2021: -$214.78M2022: -$187.06M2023: -$247.01M2024: -$358.75M2025: -$269.40M-$269.40M2019Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$269.40M+24.9%2024-$358.75M-45.2%2023-$247.01M-32.0%2022-$187.06M+12.9%2021-$214.78M-1.3%2020-$211.94M-107.6%2019-$102.09M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share